Vontobel Holding Ltd. Has $392,000 Stake in Haemonetics Co. (NYSE:HAE)

Vontobel Holding Ltd. grew its position in Haemonetics Co. (NYSE:HAE) by 3.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,878 shares of the medical instruments supplier’s stock after acquiring an additional 180 shares during the period. Vontobel Holding Ltd.’s holdings in Haemonetics were worth $392,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Capital Research Global Investors lifted its position in Haemonetics by 2.3% during the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock worth $569,690,000 after buying an additional 151,183 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Haemonetics by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock worth $462,293,000 after purchasing an additional 25,451 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Haemonetics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after purchasing an additional 57,665 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after purchasing an additional 836,623 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Haemonetics by 38.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after purchasing an additional 156,665 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Haemonetics Trading Down 0.6 %

Shares of NYSE HAE opened at $74.44 on Wednesday. Haemonetics Co. has a twelve month low of $70.74 and a twelve month high of $97.97. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of 32.51, a P/E/G ratio of 1.19 and a beta of 0.30. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. The company’s fifty day moving average is $75.67 and its 200-day moving average is $83.42.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. During the same quarter in the prior year, the firm posted $1.05 earnings per share. The business’s revenue was up 8.0% on a year-over-year basis. Equities research analysts predict that Haemonetics Co. will post 4.57 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on HAE. Barrington Research reissued an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research note on Monday, September 23rd. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. Citigroup cut their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. BTIG Research began coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target for the company. Finally, Bank of America assumed coverage on shares of Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $106.14.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.